01-26-2017 02:55 PM CET - Health & Medicine
Print

The Intravenous (IV) iron market and Oral iron market to cross US$ 3 billion by 2021

Press release from: Beige Market Intelligence
Intravenous Iron Market and Oral Iron Market - Strategic Assessment and Forecast Till 2021
Intravenous Iron Market and Oral Iron Market - Strategic Assessment and Forecast Till 2021
Report Highlights
• Market expected to cross US$ 3 billion by 2021, growing at a CAGR of 5%
• Nephrology is the largest application area of the intravenous (IV) iron and oral iron drugs
• Paradigm shift from oral iron drugs to intravenous (IV) iron drugs a major trend in the market
• The America region expected to be the largest market
• Intense competition among the vendors

A recent report released on Global Intravenous (IV) Iron and Oral Iron market – Strategic Assessment and Forecast Till 2021 covers the present scenario and the growth prospects of the iron drugs market for the period 2016-2021. The 95-page report provides in-depth market analysis of market size and growth of Global Intravenous (IV) Iron and Oral Iron market.

Click here to view report: www.beigemarketintelligence.com/reports/research-report-h...

Global intravenous IV iron and Oral iron market expected to cross US$ 3 billion by 2021, growing at a CAGR of 5%

Analysts at Beige Market Intelligence expects the global intravenous (IV) iron and oral iron market to cross US$ 3 billion by 2021, growing at an impressive CAGR close to 5%. Factors such as correction of IDA in pregnancy, growing diabetic population worldwide, growing incidence of Chronic Kidney Disease (CKD) that increases the need of dialysis, prevalence of iron deficiency are the major factors attributing to the growth of the market.

Also, huge patient population undergoing dialysis globally and patient blood management is likely to create opportunities for oral and IV drugs market. As per National Kidney Foundation, more than 2 million people globally are undergoing dialysis or a kidney transplant.

For more information: www.beigemarketintelligence.com/request-sample

Paradigm shift from oral iron drugs to intravenous (IV) iron drugs a major trend in the market

There are gastrointestinal side effects associated with oral iron drugs like nausea, constipation, anorexia, heartburn, vomiting, and diarrhoea and are intolerant even by healthy patients. Thus, the side effects of oral iron drugs have attracted the patients towards intravenous (IV) iron. Also, oral ferrous products (OFPs) cause disease in IBD patients or lead to poor compliance given intolerable side effects. Thus, side effects of OFPs, patient compliance has decreased towards OFPs and the prescription of IV iron products has increased.
Nephrology is the largest application area of the intravenous (IV) iron and oral iron drugs

Iron drugs are used in various therapeutic areas like nephrology, gynecology, oncology, gastroenterology, surgeries, and chronic heart failures. The research report provides a detailed analysis and growth forecast of each therapeutic area. Nephrology is the largest application area of the intravenous (IV) iron and oral iron drugs followed by Gynecology and Gastroenterology. Iron deficiency is a common condition among patients with chronic kidney disease (CKD).

The America region expected to be the largest market

The report includes the market analysis of global intravenous (IV) iron and oral iron market in different regions such as the Americas, APAC, and EMEA. The report outlines the major market share holder in the global intravenous (IV) iron and oral iron market and the market size analysis of all the regions. The intravenous (IV) iron and oral iron market report also provides the market size and forecast of the key countries. The America region is expected to be the largest market for intravenous (IV) iron and oral iron drugs followed by EMEA. US, Canada, and Brazil are the key countries in this region contributing a major chunk of revenue.
Large population of people suffering from CKD, diabetes and undergoing dialysis is going to spur the market for intravenous (IV) iron and oral iron in European nations. Likewise, in APAC region large population of people suffering from diabetes in major countries such as China, Japan, and India is going to propel the demand for intravenous (IV) iron and oral iron drugs. In addition, the increasing number of people undergoing renal replacement therapies in Australia and New Zealand, is expected to boost the market for intravenous (IV) iron and oral iron drugs

Intense competition among the vendors

Within the report covers the entire market outlook regarding the value chain operating within the market. The major players in the market include Actavis, AMAG Pharmaceuticals, Cipla, Indoco Remedies, Vifor Pharma.
The other leading vendors in the global intravenous (IV) iron and oral iron market include Sanofi, Arbro Pharmaceuticals, Solace Biotech, ALDE MEDI IMPEX, American Biocare.

About Beige Market Intelligence:

Beige Market Intelligence is new-age provider of competitive business intelligence, working across various industry verticals. Our expertise and knowledge ensures that the market analysis Beige provides is comprehensive, detailed and complete. The analysis helps our client organizations become aware and make educated decisions, as far as investing or devising a marketing strategy is concerned. The actionable insights delivered through our market research provide a comprehensive market analysis for every level of market segmentation in an industry. Beige Market Intelligence is a quality driven high end Market Research organization. Our team of experts ensure the analysis you receive is not just analysed and smartly presented, but is completely customized based on the client’s requirement. Our deliverables guarantee our current global client base does not look beyond Beige when it comes to any kind of industry and market analysis.

Contact info:
Khyama
Beige Market Intelligence
Chinnapannahalli Main Road, Bangalore-560037
contactus@beigemarketintelligence.com
US: +1 347 903 9949
UK: +44 20 323 99499
APAC: +91 99 012 75473

This release was published on openPR.
News-ID: 422355 • Views: 316
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: